Direct acting antiviral (DAA) treatments may reduce the elevated α fetoprotein (AFP),but data on how these treatments affect elevated AFP in patients with chronic hepatitis C (CHC) remain insufficient.In the present study,the frequency of baseline AFP elevations and their related factors,AFP dynamics during and after DAA treatment,and factors associated with AFP reduction was assessed.This retrospective study included 141 patients with CHC without hepatocellular carcinoma who received DAA and achieved sustained virological response.The details are as follows:mean post-treatment follow-up was 99 weeks (12-213);mean age,57.8 years old;52％,males;79％,genotype (GT) 1;and 47％,cirrhosis.Pre-treatment AFP elevation (＞ 5.5 ng/mL) was seen in 48.2％ patients.On multivariate analysis,baseline AFP ＞ 5.5 was associated with the presence of cirrhosis (P =0.001),coexisting non-alcoholic steatohepatitis (NASH) (P =0.035),and GT 1 (P =0.029).AFP normalization was seen in 28.2％ patients at treatment week 2,in 52％ at the end of treatment,and in 73.4％ at the end of follow-up.Posttreatment week 24 AFP normalization was associated with the absence of cirrhosis (P =0.003),Child-Pugh score ＜ 6 (P =0.015),and baseline AFP ＜ 10 (P =0.015).AFP elevation is common in patients with CHC and independently associated with NASH,cirrhosis,and GT 1.DAA treatment resulted in AFP normalization as early as treatment week 2.Post-treatment week 24 AFP normalization is independently associated with the absence of cirrhosis,Child-Pugh score ＜ 6,and baseline AFP ＜ 10.